What are the indications, recommended dosing regimen, dose adjustments for renal or hepatic impairment, contraindications, common adverse effects, monitoring recommendations, and alternative antiseizure medications for lacosamide in adults with focal (partial‑onset) seizures?

Lacosamide for Focal-Onset Seizures in Adults

Lacosamide is an effective and well-tolerated third-generation antiseizure medication approved as both adjunctive therapy and monotherapy for focal (partial-onset) seizures in adults, with a favorable safety profile compared to older agents.

Indications

Lacosamide is FDA-approved for:

• Adjunctive therapy for focal-onset seizures with or without secondary generalization in adults and adolescents ≥16 years 1, 2
• Monotherapy for focal-onset seizures (demonstrated noninferiority to carbamazepine controlled-release) 2
• Available in both oral (tablet, syrup) and intravenous formulations 1, 3

While not specifically mentioned in older WHO guidelines that prioritize carbamazepine, phenobarbital, phenytoin, and valproic acid for resource-limited settings 4, lacosamide represents a newer-generation option with advantages in tolerability 5.

Dosing Regimen

Standard Adjunctive Therapy

• Initial dose: 50 mg twice daily (100 mg/day)
• Titration: Increase by 100 mg/day at weekly intervals
• Maintenance dose: 200-400 mg/day (100-200 mg twice daily) 6, 3
• Maximum dose: 600 mg/day, though doses above 400 mg/day show minimal additional efficacy with increased adverse effects 6

Loading Dose for Seizure Clusters

• IV loading: 200-300 mg achieves 89% response rate 7
• Doses <200 mg show significantly lower efficacy (29% response rate) 7
• IV and oral formulations are bioequivalent and interchangeable at the same dose 2, 3

Monotherapy

• Target maintenance: 300-600 mg/day in divided doses 2
• Efficacy sustained for up to 2 years 2

Critical titration note: Slower titration reduces dose-related adverse effects, particularly during the initial 4-6 week period 6.

Dose Adjustments

Renal Impairment

• Mild-to-moderate impairment (CrCl 30-80 mL/min): No dose adjustment necessary 8, 9
• Severe impairment (CrCl <30 mL/min): Maximum dose 300 mg/day (reduce by ~25-30%) 8, 9
• End-stage renal disease/hemodialysis:
  • Maximum 300 mg/day
  • Supplement with additional 50% of daily dose after each hemodialysis session (removes ~50% of drug) 8, 9

Hepatic Impairment

• Mild-to-moderate impairment: Maximum dose 300 mg/day 10, 9
• Severe hepatic impairment: Use with extreme caution; maximum 300 mg/day 9
• Lacosamide may be safer than phenobarbital in cirrhotic patients (case report showed phenobarbital precipitated hepatic encephalopathy while lacosamide did not) 10

Contraindications

Absolute contraindications:

• Known hypersensitivity to lacosamide or any component 11
• Second- or third-degree AV block (without pacemaker) 11

Relative contraindications/Use with extreme caution:

• Severe cardiac conduction abnormalities 11
• History of psychiatric disorders (depression, psychosis) 11
• Previous allergic reactions to antiseizure medications 11
• Severe hepatic impairment 9

Common Adverse Effects

Most Frequent (>10% incidence)

The dose-related adverse effects predominantly occur during titration 6:

• Dizziness: 30.6% (vs 8.2% placebo) - most common
• Diplopia: 10.5% (vs 1.9% placebo)
• Nausea: 11.4% (vs 4.4% placebo)
• Headache: Common but less specific 6, 3

Severity Profile

• Most adverse effects are mild-to-moderate 12, 6
• Severe adverse effects predominantly at 600 mg/day dose 6
• Adverse effects more common during titration than maintenance phase 6

Serious Adverse Effects (Rare but Important)

• DRESS syndrome (Drug Rash with Eosinophilia and Systemic Symptoms) 11
• Cardiac conduction disturbances (rhythm abnormalities, AV block) 11
• Psychiatric effects: Depression, psychosis, suicidal ideation 11
• Hyponatremia: Monitor sodium levels periodically 11

Discontinuation Rates

• 200 mg/day: 8.1%
• 400 mg/day: 17.2%
• 600 mg/day: 28.6%
• Placebo: 4.9% 6

Common pitfall: Discontinuation rates vary by concomitant AED—highest with carbamazepine (15.3%) and lamotrigine (19.2%), lowest with levetiracetam (10.1%) 6.

Monitoring Recommendations

Baseline Assessment

• ECG: Mandatory in patients with cardiac history or risk factors 11
• Serum sodium: Baseline level 11
• Psychiatric history: Screen for depression, psychosis 11
• Renal function: Calculate creatinine clearance 8
• Hepatic function: Liver enzymes if hepatic disease suspected 10

Ongoing Monitoring

• ECG monitoring: Required in patients with cardiac disease or conduction abnormalities 11
• Serum sodium: Periodic monitoring, especially if symptoms of hyponatremia develop 11
• Psychiatric symptoms: Regular assessment for mood changes, suicidal ideation 11
• Skin reactions: Monitor for rash, especially in first 8 weeks 11
• Therapeutic drug monitoring: Not routinely required but may be beneficial in special populations (pregnancy, drug interactions, suspected non-adherence) 13

Driving Considerations

• Acute administration: May impair driving performance 5
• Chronic administration: Does NOT result in clinically meaningful driving impairment 5
• Incidence of arousal-related adverse events with lacosamide is lower than carbamazepine 5

Alternative Antiseizure Medications

First-Line Alternatives for Focal Seizures

Carbamazepine remains the preferred first-line agent in resource-limited settings 4:

• Specifically recommended for partial-onset seizures in WHO guidelines 4
• Lower cost but more drug interactions and adverse effects

Levetiracetam 12:

• Comparable efficacy to lacosamide
• Fewer cardiac concerns
• May cause behavioral/psychiatric effects
• Useful in status epilepticus (30-50 mg/kg IV load) 12

Lamotrigine 14:

• 50% responder rate: 20-22% at 300-400 mg/day
• Requires slow titration (risk of serious rash)
• Better cognitive profile

Valproate 12:

• Effective for both focal and generalized seizures
• Avoid in women of childbearing potential 4
• Useful in status epilepticus (20-30 mg/kg IV) 12

Second-Line Alternatives

Topiramate 14:

• 50% responder rate: 27-50% at 200-600 mg/day
• Cognitive side effects common
• Weight loss may be beneficial or problematic

Oxcarbazepine 14:

• 50% responder rate: 50% at 2,400 mg/day
• Better tolerated than carbamazepine
• Risk of hyponatremia

Gabapentin 14:

• Well-tolerated but less effective
• No drug interactions
• Useful in elderly

Emerging Alternatives

Brivaracetam 9:

• Similar mechanism to levetiracetam
• Minimally affected by renal impairment

Perampanel 9, 11:

• Once-daily dosing
• Psychiatric side effects require monitoring
• Highly protein-bound (requires free-drug monitoring in organ impairment)

Cenobamate 9, 11:

• High efficacy but requires strict dose caps in severe organ dysfunction
• Risk of DRESS syndrome

Key Clinical Pearls

• Lacosamide offers a favorable balance: Efficacy comparable to older agents with better tolerability profile, particularly regarding cognitive effects 5, 2
• Dose optimization: 400 mg/day appears to be the optimal dose—higher doses (600 mg/day) show minimal additional benefit with significantly more adverse effects 6
• Cardiac screening is essential: ECG mandatory before initiating in patients with cardiac history 11
• Drug interactions are minimal: Unlike enzyme-inducing AEDs, lacosamide has predictable pharmacokinetics 13
• IV-to-oral conversion is seamless: Same dose, no adjustment needed 2, 3
• Avoid rapid titration: Slower titration significantly reduces adverse effects without compromising efficacy 6